A new study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
MEDIZIN.NEWZS.de – Quantum Related Diseases Research Group (QRDRG)
Forschungsgruppe Quanteneffekte bei Krankheiten (qrdrg.xonl.de)